Seqirus’s FLUCELVAX® cell-based quadrivalent influenza vaccine has been approved to expand the age indication to children as young as 6 months of age by the US Food and Drug Administration.
The US Food and Drug Administration has approved the FLUCELVAX® cell-based quadrivalent influenza vaccine for an expanded age indication for children as young as 6 months of age.1 The vaccine is now indicated for any patient who is eligible to receive an influenza vaccine in the United States.
The approval was based on phase 3 clinical trial data that showed the vaccine was as immunogenic and safe as the standard quadrivalent seasonal influenza vaccine in children 6 months of age to <4 years during the 2019 to 2020 annual influenza season. In the trial 2414 children were randomized to receive either FLUCELVAX® or the standard quadrivalent vaccine.
Depending on vaccination history, a child received either 1 or 2 vaccine doses. Following immunization, participants received at least 180 days of follow-up and noninferiority of FLUCELVAX® was determined. The safety of the FLUCELVAX® vaccine was comparable to the standard vaccine and common adverse events included tenderness, irritability, and erythema at the site of injection. Complete data from the clinical trial was presented at the Pediatric Academic Society virtual Annual Meeting earlier in 2021.
Cell-based vaccines are meant to exactly replicate the influenza virus strains chosen by the World Health Organization. Because they avoid egg-adapted changes, they may potentially have greater effectiveness than other vaccine forms.
This article was originally published on Contemporary Pediatrics®.
Reference
1. Seqirus. Seqirus receives FDA approval of its cell-based quadrivalent influenza vaccine, expanding the age indication to include children as young as six months. Published October 15, 2021. Accessed October 18, 2021. https://www.multivu.com/players/English/8933751-seqirus-fda-approval-of-cell-based-quadrivalent-influenza-vaccine-for-people-six-months-and-older/
Rising endometriosis rates linked to increased pregnancy complications
May 19th 2024A new study presented at the 2024 ACOG meeting reveals a significant rise in endometriosis among pregnant women over the past 20 years, linking the condition to increased obstetric and neonatal complications.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Impact of antiepileptic medications and sex hormones on maternal and child outcomes in epilepsy
May 16th 2024Paula Emanuela Voinescu, MD, PhD, director of the Women's Epilepsy Program at Brigham and Women's Hospital, talked about the influence of sex hormones on maternal outcomes in pregnant women with epilepsy treated with antiseizure medication.
Read More
Echogenic Mass identified as key predictor for retained products of conception
May 13th 2024Discover how recent findings highlight the significance of echogenic masses in accurately diagnosing post-pregnancy complications, shedding light on effective management strategies and reducing the need for invasive interventions.
Read More